get a key
steadybase-$ company MDWD
account_id none on file
legal_name MediWound Ltd.
ticker MDWD
cik 1593984
domain mediwound.com
entry_point_account_id none on file
exchange Nasdaq
sector Health Care
calls 1 filings 22 executives 1 family 0
why_nownone on file
calls
Second, The travel and visit requirements associated with the protocol created participation challenges for the older and medically complex VLU patient population. To support enrollment and reduce participation burden, we implemented patient assistance measures, including hotel reimbursements, transportation services, and facilitated access to enhanced care.

May 27, 2026 / receipt, needs a key / Ofer Gonen, CEO | earnings call 2026-05-27 | transcript 6afe0ebd-9c18-4a4f-a320-8a3cb837c9f7 | chars 3666-4026 | segment 3

filings
pay and travel expenses. We generally provide our employees with benefits and working conditions beyond the required minimums.

filing / Mar 5, 2026 / receipt

We leased approximately 4,000 square feet of additional office space in Gan Rave, Israel, pursuant to a two-year lease agreement that commenced on January 1, 2024 and was expired effective March 31, 2025.

filing / Mar 5, 2026 / receipt

our revenue growth, timing of milestone payments, the timing and extent of our spending on research and development efforts, and international

filing / Mar 5, 2026 / receipt

The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our drugs.

filing / Mar 5, 2026 / receipt

In addition to continuing pressure on prices and cost containment measures, legislative developments at the EU or member state level may result in significant additional requirements or obstacles that may increase our operating costs.

filing / Mar 5, 2026 / receipt

6X Capacity Increase1

ir_statement / Sep 9, 2026 / receipt

Facility Scale-Up Supports Future Growth1

ir_statement / Sep 9, 2026 / receipt

Full manufacturing capacity anticipated in 2025/6

ir_statement / Sep 9, 2026 / receipt

Global demand exceeds current manufacturing capability 3X

ir_statement / Sep 9, 2026 / receipt

2. 2028 outlook includes revenue contribution related to EscharEx, subject to regulatory approval

ir_statement / Sep 9, 2026 / receipt

Commercial readiness/ execution

ir_statement / Sep 9, 2026 / receipt

Expanded facility

ir_statement / Sep 9, 2026 / receipt

executives
familynone on file
upcoming
2026-11-19 earnings call scheduled ir
changesnone on file
mcp_package_hint
steadybase-$